Table 5.
Grade 3 and higher toxicities according to treatment strategy during induction therapy
| CTX/ATRA & CTX/ATO/ATRA a no. (%) | ATO/ATRA no. (%) | P-value | |
|---|---|---|---|
| Febrile neutropenia | 23/34 (68) | 3/11 (27) | 0.03 |
| Hematological adverse eventsb | 32/34 (94) | 9/11 (82) | 0.25 |
| c Other adverse events | 30/41 (73) | 11/15 (73) | 1.00 |
Abbreviations: ATO, arsenic trioxide; ATRA, all-trans retinoic acid; CTX, chemotherapy; No, numbers. Denominators are not consistent with the total number of patients of the respective treatment group due to missing values.
a
Patients who received CTX/ATRA or CTX/ATO/ATRA were categorized into one group since ATO in the latter group was given during consolidation therapy only.34
b
Anemia and/or thrombopenia and/or neutropenia.
c
Other adverse events: adverse events excluding anemia, thrombopenia or neutropenia. Toxicities were classified according to CTCAE v. 4.0.